Drug Trial Radar · NCT06516042
Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia
Last checked: Nov 20, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10,350
Planned (sponsor's estimate)
Start
Aug 21, 2024
Primary completion
Jan 24, 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- PATHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Federal Minstry of Health of Ethiopia
- First posted
- Jul 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the effectiveness, feasibility, and acceptability of targeted drug administration for seasonal migrant populations in Metema District, Amhara Region, Ethiopia
Conditions
- Plasmodium Falciparum
- Malaria
Interventions
Dihydroartemisinin-piperaquineDrug
Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasmodium falciparum (Pf) parasite prevalenceTime frame: Up to 6 months
- Feasibility of TDATime frame: Up to 6 months
- Acceptability of TDA amongst farmworkers, farm-site owners, and local health authoritiesTime frame: Up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Delello Farm Sites
Gonder, Metema District, Ethiopia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.